Trial Details

Not Recruiting
Basic Information
Clinical ID c3227
Identifier EUCTR2011-000897-80-BE
Trial Title PHASE II RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF rhuMAb BETA7 IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
Trial URL Visit Original Page
Study Information
Study Results

No results available
Conditions Ulcerative colitis MedDRA version: 14.0_Level: LLT_Classification code 10045365_Term: Ulcerative colitis_System Organ Class: 10017947 - Gastrointestinal disorders_;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Interventions Product Name: rhuMAb Beta7 Product Code: PRO145223 (RO5490261) Pharmaceutical Form: Solution for injection INN or Proposed INN: n.a. Current Sponsor code: PRO145223 (RO5490261) Other descriptive name: rhuMAb Beta7 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use
Participant Information
Sponsor Genentech, Inc.
City -
Country/Region United States;Hungary;Czech Republic;Canada;Spain;Belgium;Australia;Israel;Germany;United Kingdom;New Zealand
Enrollment Criteria
Sex Requirement NOT SPECIFIED
Age Requirement -
Study Design
Study Type Interventional clinical trial of medicinal product
Phase PHASE2
Time Information
Start Date 2025-04-24
Primary Completion Date -
Completion Date -